TY - JOUR
T1 - Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
AU - Sasaki, Koji
AU - Kantarjian, Hagop M.
AU - Jain, Preetesh
AU - Jabbour, Elias J.
AU - Ravandi, Farhad
AU - Konopleva, Marina
AU - Borthakur, Gautam
AU - Takahashi, Koichi
AU - Pemmaraju, Naveen
AU - Daver, Naval
AU - Pierce, Sherry A.
AU - O'Brien, Susan M.
AU - Cortes, Jorge E.
N1 - Publisher Copyright:
© 2015 American Cancer Society.
PY - 2016/1/15
Y1 - 2016/1/15
N2 - BACKGROUND Tyrosine kinase inhibitors (TKIs) significantly improve survival in patients with chronic myeloid leukemia in chronic phase (CML-CP). Conditional probability provides survival information in patients who have already survived for a specific period of time after treatment. METHODS Cumulative response and survival data from 6 consecutive frontline TKI clinical trials were analyzed. Conditional probability was calculated for failure-free survival (FFS), transformation-free survival (TFS), event-free survival (EFS), and overall survival (OS) according to depth of response within 1 year of the initiation of TKIs, including complete cytogenetic response, major molecular response, and molecular response with a 4-log or 4.5-log reduction. RESULTS A total of 483 patients with a median follow-up of 99.4 months from the initiation of treatment with TKIs were analyzed. Conditional probabilities of FFS, TFS, EFS, and OS for 1 additional year for patients alive after 12 months of therapy ranged from 92.0% to 99.1%, 98.5% to 100%, 96.2% to 99.6%, and 96.8% to 99.7%, respectively. Conditional FFS for 1 additional year did not improve with a deeper response each year. Conditional probabilities of TFS, EFS, and OS for 1 additional year were maintained at >95% during the period. CONCLUSIONS In the era of TKIs, patients with chronic myeloid leukemia in chronic phase who survived for a certain number of years maintained excellent clinical outcomes in each age group.
AB - BACKGROUND Tyrosine kinase inhibitors (TKIs) significantly improve survival in patients with chronic myeloid leukemia in chronic phase (CML-CP). Conditional probability provides survival information in patients who have already survived for a specific period of time after treatment. METHODS Cumulative response and survival data from 6 consecutive frontline TKI clinical trials were analyzed. Conditional probability was calculated for failure-free survival (FFS), transformation-free survival (TFS), event-free survival (EFS), and overall survival (OS) according to depth of response within 1 year of the initiation of TKIs, including complete cytogenetic response, major molecular response, and molecular response with a 4-log or 4.5-log reduction. RESULTS A total of 483 patients with a median follow-up of 99.4 months from the initiation of treatment with TKIs were analyzed. Conditional probabilities of FFS, TFS, EFS, and OS for 1 additional year for patients alive after 12 months of therapy ranged from 92.0% to 99.1%, 98.5% to 100%, 96.2% to 99.6%, and 96.8% to 99.7%, respectively. Conditional FFS for 1 additional year did not improve with a deeper response each year. Conditional probabilities of TFS, EFS, and OS for 1 additional year were maintained at >95% during the period. CONCLUSIONS In the era of TKIs, patients with chronic myeloid leukemia in chronic phase who survived for a certain number of years maintained excellent clinical outcomes in each age group.
KW - chronic myeloid leukemia
KW - conditional survival
KW - response
KW - tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84954076925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954076925&partnerID=8YFLogxK
U2 - 10.1002/cncr.29745
DO - 10.1002/cncr.29745
M3 - Article
C2 - 26479889
AN - SCOPUS:84954076925
SN - 0008-543X
VL - 122
SP - 238
EP - 248
JO - Cancer
JF - Cancer
IS - 2
ER -
